CPA
BCRX icon

Capital Performance Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capital Performance Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,512
Closed -$11.5K – 454
2024
Q3 		$11.5K Buy
+1,512
New +$11.5K ﹤0.01% 786

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Performance Advisors's BCRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 1,512 shares — an estimated $11.5K sold.

Capital Performance Advisors first reported a position in BCRX in Q3 2024 and held it in 1 quarter. The position peaked at $11.5K in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,512 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $11.5K.
  • Capital Performance Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's BioCryst Pharmaceuticals position peaked at $11.5K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.